Evidence map›Paper›PMID 22880042›Full record

ArticlePloS one2012

HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses.

Nicholas J Steers, Silvia Ratto-Kim, Mark S de Souza, Jeffrey R Currier, Jerome H Kim, Nelson L Michael, Carl R Alving, Mangala Rao

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Liposome Formulations as Adjuvants for Vaccines.Current topics in microbiology and immunology · 2021
    Article
  5. Review
  6. Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Nicholas J SteersUnited States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Silvia Ratto-Kim
Mark S de Souza
Jeffrey R Currier
Jerome H Kim
Nelson L Michael
Carl R Alving
Mangala Rao
Walter Reed Army Institute of Research · USHenry M. Jackson Foundation · USArmed Forces Research Institute of Medical Science · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntigen processing involves many proteolytic enzymes such as proteasomes and cathepsins. The processed antigen is then presented on the cell surface bound to either MHC class I or class II molecules and induces/interacts with antigen-specific CD8+ and CD4+ T-cells, respectively. Preliminary immunological data from the RV144 phase III trial indicated that the immune responses were biased towards the Env antigen with a dominant CD4+ T-cell response.

methodsIn this study, we examined the susceptibility of HIV-1 Env-A244 gp120 protein, one of the protein boost subunits of the RV144 Phase III vaccine trial, to proteasomes and cathepsins and identified the generated peptide epitope repertoire by mass spectrometry. The peptide fragments were tested for cytokine production in CD4(+) T-cell lines derived from RV144 volunteers.

resultsEnv-A244 was resistant to proteasomes, thus diminishing the possibility of the generation of class I epitopes by the classical MHC class I pathway. However, Env-A244 was efficiently cleaved by cathepsins generating peptide arrays identified by mass spectrometry that contained both MHC class I and class II epitopes as reported in the Los Alamos database. Each of the cathepsins generated distinct degradation patterns containing regions of light and dense epitope clusters. The sequence DKKQKVHALF that is part of the V2 loop of gp120 produced by cathepsins induced a polyfunctional cytokine response including the generation of IFN-γ from CD4(+) T-cell lines-derived from RV144 vaccinees. This sequence is significant since antibodies to the V1/V2-loop region correlated inversely with HIV-1 infection in the RV144 trial.

conclusionsBased on our results, the susceptibility of Env-A244 to cathepsins and not to proteasomes suggests a possible mechanism for the generation of Env-specific CD4(+)T cell and antibody responses in the RV144 vaccinees.

Indexed as

AIDS VaccinesAmino Acid SequenceCathepsinsCD4-Positive T-LymphocytesEpitopesHIV-1HIV Envelope Protein gp120HumansImmunityInterferon-gammaLeukocytes, MononuclearModels, ImmunologicalMolecular Sequence DataPeptidesProteasome Endopeptidase ComplexProteolysisAIDS VaccinesCathepsinsEpitopesHIV Envelope Protein gp120Interferon-gammaPeptidesProteasome Endopeptidase Complex

Identifiers

PMID22880042
PMCPMC3412807
OpenAlexW2136443055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.